Psoriasis patients get second chance with higher drug dose
NCT ID NCT01680159
First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tested a higher dose (10 mg/kg every 8 weeks) of the drug TA-650 in 51 adults with psoriasis whose symptoms had returned after initially responding to the standard dose of Remicade. The goal was to see if the higher dose could again improve skin symptoms. The study measured how many patients achieved at least a 75% improvement in their psoriasis area and severity score.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational site
Chugoku, Japan
-
Investigational site
Chūbu, Japan
-
Investigational site
Hokkaido, Japan
-
Investigational site
Kanto, Japan
-
Investigational site
Kinki, Japan
-
Investigational site
Kyushu, Japan
-
Investigational site
Tōhoku, Japan
Conditions
Explore the condition pages connected to this study.